What we stand for


endsulin is a start-up company with to cure Type I Diabetes with Gene Therapy. Hans Sollinger, MD has discovered and patented a DNA sequence which is glucose responsive and promotes the activation of the human insulin gene in a physiological fashion. This gene is called Diatagene. They are the first ones to publish data demonstrating that glucose control, and insulin disappearance after glucose stimuli, follow an absolute perfect physiological pattern. Work performed in 2013 is focused on improvements of gene delivery and long-term expression. With approximately 5 million Type I diabetics in developed nations, there is a huge potential market as diabetics would require only a one-time single injection, and are expected to have much better glucose control.

Our Management Team


    MR. JAY. W. HANDY Acting CEO

    Jay is the Acting CEO of an investment management company. Prior to starting this company, Jay served as managing director of Merrill Lynch in Madison, WI. He has partaken in many national forums on diabetes, including HHS Secretary Tommy Thompson’s diabetes health initiatives. He is a graduate of Michigan State University and Harvard Business School. Jay has managed his own diabetes for 40 years.

    MR. JEFF RUSINOW Chairman

    Jeff Rusinow has been an active member of early-stage venture capital for over the past 15 years, and was the founder of Milwaukee’s first angel network. He has been chairman and lead investor in two startups that have been acquired by Fortune 500 companies. He spent 22 years in retail management, holding senior executive positions at Macy’s, Gimbel’s, Hudson Bay Company and Kohl’s Department Stores. Jeff has a B.A. and M.A. from the University of Virginia.

  • Sussie Wolff
    Sussie Wolff Pediatrician

    Proin consequat, at commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit.